New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
18:48 EDTNPSP, LMT, KKD, GWRE, SHPG, ZQKOn The Fly: After Hours Movers
UP AFTER EARNINGS: Guidewire (GWRE), up over 1% after reporting better than expected Q3 results and giving guidance on its conference call. ALSO HIGHER: Lockheed Martin (LMT), up fractionally after being awarded a $914.7M Space Fence contract. DOWN AFTER EARNINGS: Quiksilver (ZQK), down 30%... Krispy Kreme Doughnuts (KKD), down 10.5%. ALSO LOWER: NPS Pharmaceuticals (NPSP), down almost 1% after disclosing in a filing that it has not had any communication with Shire (SHPG) concerning a purported acquisition offer.
News For GWRE;LMT;ZQK;KKD;NPSP;SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
February 25, 2015
06:14 EDTSHPGPTC Therapeutics takeout price likely tops $100/share, said Credit Suisse
Credit Suisse yesterday raised its price target for PTC Therapeutics (PTCT) shares to $100 from $66 after Reuters reported the drug market is starting a sale process with Shire (SHPG) and Biomarin (BMRN) as possible suitors. The firm believes a takeout is a likely outcome before or after data the Phase III data expected to be announced in October. PTC has Translarna Phase III trials ongoing in Duchenne muscular dystrophy and cystic fibrosis to support full approval in the U.S. Credit Suisse said yesterday in a note to investors that a takeout value for the company likely exceeds $100 per share. It believes PTC would be a good fit for Vertex (VRTX), Biogen (BIIB), Roche (RHHBY) and others. The firm kept an Outperform rating on the stock. PTC Therapeutics shares closed yesterday up $6.20 to $71.16.
February 24, 2015
17:19 EDTLMTLockheed Martin awarded $129M government contract modification
Subscribe for More Information
07:05 EDTSHPGShire acquires Meritage Pharma
Subscribe for More Information
February 23, 2015
16:27 EDTSHPGOn The Fly: Closing Wrap
Stocks on Wall Street began the session in negative territory and remained there for most of the session, with the Nasdaq the lone index to post a small gain. The Dow was weighed down by shares of Boeing (BA), which slid after the stock received a downgrade. There was little in the way of positive economic news, as the most notable report showed existing homes were lower than expected due to a shortage of inventory. The averages drifted for most of the session, as investors may be waiting on the sidelines ahead of tomorrow’s banking panel testimony by Fed Chair Janet Yellen. ECONOMIC EVENTS: In the U.S., the Chicago Fed national activity index rebounded to 0.13 in January, which was nearly in-line with expectations. Existing home sales dropped 4.9% to a 4.82M rate in January, which was much worse than the expected 1.8% drop to a 4.95M unit rate. In Europe, the Ifo Institute’s measure of German business confidence rose to 106.8 in February, which was up a tenth of a percentage point from the previous month but below the 107.7 consensus forecast. Also, the Bank of Israel became the latest central bank to cut rates this year, lowering its main interest rate to 0.1% from 0.25%. COMPANY NEWS: The shares of a number of health insurers rose after the Centers for Medicare and Medicaid Services, or CMS, issued preliminary 2016 Medicare Advantage rates. According to Credit Suisse, the rates were favorable for the insurers. Following the CMS announcement made late Friday, Humana (HUM) climbed $8.40, or 5.38%, to $164.52, UnitedHealth (UNH) rose $3.78, or 3.36%, to $116.40, and WellCare (WCG) gained $4.68, or 5.53%, to $89.30. MAJOR MOVERS: Among the notable gainers was PTC Therapeutics (PTCT), which jumped $9.77, or 17.7%, to $64.96 after Reuters said the company is working with financial advisers to explore a potential sale after receiving takeover interest from several companies including Shire (SHPG) and BioMarin (BMRN). Also higher was Valeant (VRX), which rose $25.49, or 14.71%, to $198.75 after the company agreed to buy Salix (SLXP) for $158 per share and also reported better-than-forecast earnings. Salix shares, however, fell $2.09, or 1.32%, to $155.76, as a report Friday from CNBC's David Faber telegraphed the deal and suggested Valeant could value Salix around $160 per share. Among the noteworthy losers was Spectrum Pharmaceuticals (SPPI), which dropped $1.18, or 15.82%, to $6.28 after a judge ruled that a drug which could compete with the company's Fusilev treatment does not infringe on the company's intellectual property. Also lower were shares of Boeing, which fell $3.57, or 2.26%, to $154.74 after the stock was downgraded to Sell from Neutral at Goldman Sachs. INDEXES: The Dow fell 23.60, or 0.13%, to 18,116.84, the Nasdaq gained 5.01, or 0.1%, to 4,960.97, and the S&P 500 slipped 0.64, or 0.03%, to 2,109.66.
13:30 EDTLMTIsrael to purchase another 14 of Lockheed Martin's F-35s, Globes says
Subscribe for More Information
12:53 EDTSHPGAnalysts debate potential for competing Salix takeover bid
Subscribe for More Information
12:29 EDTSHPGPTC Therapeutics exploring potential sale, Reuters reports
Subscribe for More Information
07:55 EDTSHPGJefferies says other bidders may emerge for Salix
Jefferies says it could envision other bidders emerging for Salix (SLXP) and points out recent media reports have suggested Shire (SHPG) and Endo (ENDP) have considered making a bid for the company. It lists AstraZeneca (AZN) and Takeda as others who could have possible interest in Salix. The firm believes Valeant (VRX) could afford to pay more for Salix should other bidders emerge.
06:42 EDTLMTLockheed Martin to pay $62M to settle retirement plan lawsuit, WSJ says
Lockheed Martin will pay $62M to settle a civil suit alleging its 401(k) plan charged unreasonable fees, reports the Wall Street Journal, citing legal filings and company statements. As part of the settlement, Lockheed will also have to submit monthly evaluations of certain aspects of its plan, offer new low-cost funds, and solicit bids from at least three large firms to serve as administrative managers of the company's retirement plans. Reference Link
February 22, 2015
18:04 EDTSHPG, NPSPShire completes acquisition of NPS Pharma
Shire (SHPG) announces the successful completion of the tender offer for all of the outstanding shares of NPS Pharmaceuticals (NPSP) and the subsequent acquisition of NPS Pharma.The tender offer expired at 12:00 midnight, New York City time, at the end of Friday, February 20, and was not extended. As of the expiration of the tender offer, a total of approximately 88,869,118 common shares of NPS Pharma had been validly tendered and not withdrawn pursuant to the tender offer, representing approximately 81.7% of the outstanding common shares of NPS Pharma. All shares that were validly tendered and not withdrawn pursuant to the tender offer were accepted for payment. After the acceptance of shares that were validly tendered and not withdrawn pursuant to the tender offer, Shire completed the acquisition of NPS Pharma today through a merger of one of Shire's subsidiaries with and into NPS Pharma. In connection with the merger, all common shares of NPS Pharma that were not accepted for payment in the tender offer (excluding any shares held by NPS Pharma as treasury stock (other than any shares held in an NPS Pharma benefit plan) and any shares with respect to which the holders have properly demanded appraisal rights in accordance with Delaware law) were converted into the right to receive $46.00 per share in cash, without interest and less any applicable withholding taxes, the same price that will be paid for shares accepted for payment in the tender offer. Following completion of the merger, NPS Pharma became a wholly owned subsidiary of Shire and NPS Pharma's shares ceased to be traded on NASDAQ.
15:59 EDTSHPGValeant to buy Salix for $10.1B, FT says
Subscribe for More Information
February 20, 2015
07:08 EDTSHPGAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
09:38 EDTLMTLockheed Martin says getting 'very excited' for laser weapon development
Subscribe for More Information
09:13 EDTLMTLockheed says international growth would still be fairly healthy excluding F-35
Lockheed says F-35 makes up "lion's share" of growth internationally and domestically. Lockheed Martin CFO Bruce Tanner is speaking at the Barclays Industrial Select Conference.
07:46 EDTLMTAustralia opens bids for $8B armored vehicle defense contract, WSJ says
Subscribe for More Information
07:12 EDTNPSPWharton Health Care Club to hold a conference
Subscribe for More Information
05:55 EDTLMTLockheed Martin on track to cut cost of F35 jets by 30%, Financial Times reports
Subscribe for More Information
February 18, 2015
16:06 EDTLMTLockheed Martin names Dana Jackson as Chief Technology Officer
Subscribe for More Information
February 17, 2015
18:06 EDTSHPGPaulson & Co gives quarterly update on stakes
Subscribe for More Information
09:12 EDTSHPGShire multiple poised to expand, says SunTrust
SunTrust believes that Shire's rare disease unit will account for 40% of its 2020 sales, versus the company's estimate of about 35%. As a result, the firm expects the company's multiple to "re-rate." The firm thinks that the company's long-term growth outlook is underappreciated, and it keeps a $262 price target and Buy rating on the shares.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use